Navigation Links
Hard To Treat Diseases (HTDS) Offers Hepatitis A Vaccine in India
Date:4/3/2009

SHENZHEN, China, April 3 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that its China based operating subsidiary Mellow Hope has surpassed sales of 200,000 units of Hepatitis A Vaccine in India.

The Hepatitis A Vaccine (BIOVAC-A) was first launched in the market of India in December, 2005. Terry Yuan, CEO added "Because our product is single-dose vaccine, so (sic) our price is almost the half of other multinational competitors' price. Our sales volume keeps growing continuously. To well promote our AV and convince the local people that our product is equal or better to our multinational competitors, we had conducted a Multi-centric clinical trial in 2007. The results proved that our product offers great safety and efficacy. Subsequently, this trial report was published in the International Journal. As a company, we hold two seminars' every year, one in India and one in China".

The company will provide further details as they become available.

Safe Harbor

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. World-first high blood pressure treatment trialled in Melbourne
2. New Antibiotic Could Shorten TB Treatment
3. Plain-Language Guides Detail Insulin Treatments
4. More compelling evidence on why earlier HIV treatment lengthens survival
5. Treating Complicated Grief -- New NIMH Study Seeks 200 Older Adults Suffering from Unrelenting Symptoms of Complicated Grief for Participation in Non-Drug Clinical Trial
6. Solta Medical Presents Expert Roundtable about Thermage(R) and Fraxel(R) Combination Treatments at ASLMS Annual Meeting
7. Xanodynes New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
8. Some radiation therapy treatments can decrease fertility
9. Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
10. Doctors at Henry Ford Health System Treat Ovarian, Prostate, Lung, and Other Forms of Cancer Using Novalis Tx(TM) Platform for Image-Guided Radiosurgery
11. If You Treated an Illinois Workers Compensation Patient or a Patient Covered by an Illinois Automobile Insurance Policy and Your Bill was Reduced by a Discount Pursuant to a First Health or CCN PPO Network, Please Read This Notice Carefully As It Affects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, Doctors on ... to help personal injury victims find high quality medical care. When the company started ... area. Fast forward to present day and the now ten-page directory features a vast ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland ... autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched ... other caregivers the opportunity to share stories and advice, seek help, and continue their ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... inspirational interview of two ostomy patients, standing as living proof that attitude and ... from digestive diseases and issues that spike around the holidays. This campaign will ...
(Date:12/2/2016)... Delaware (PRWEB) , ... December 02, 2016 , ... ... released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps ... sample entry through labeling, storing, shipping and disposal. The new version is a ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ... and night. No other wearable health technology on the market can deliver all that ... poeple more meaningful insights about their health than the usual heart rate and steps ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  The Addiction Treatment Advisory ... of Managed Care Pharmacy (AMCP), has released detailed ... address the opioid addiction crisis, including through improved ... ATAG,s newly released paper, "The Role ... Naloxone," addresses many issues around gaps and barriers ...
(Date:12/2/2016)...  Maxor National Pharmacy Services, LLC ("Maxor"), today announced that ... The combination of Texas -based Maxor Specialty ... bring together both company,s clinical expertise and high-touch patient service ... specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... -- CVS Health Corporation (NYSE: CVS ) ... December 15, 2016, beginning at 8:00 a.m. (ET). Senior members ... in-depth review of the company,s strategies to drive long-term ... discuss 2017 earnings guidance during the event. ... be broadcast simultaneously on the Investor Relations portion of ...
Breaking Medicine Technology: